We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Labcyte Software Expands Echo™ Applications to Secondary Screening

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Labcyte Inc. has announced the release of two software products, one to set up dose-response assays and the other to facilitate cherry-picking, that enhance the applications of its Echo technology.

The Echo 550 and Echo 555 liquid handlers use acoustic energy to transfer nanoliter volumes of fluids, eliminating pipettes, pin tools and nozzles.

The Dose-Response software makes it easy for users of Echo systems to set-up multi-point dose-response assays typical of those analyses used for IC50 and EC50 determinations.

The use of Echo technology eliminates complicated serials dilutions and the negative impact they have on analyses.

Bristol-Myers Squibb reported in a scientific poster that Echo technology used in IC50 analyses eliminated a large number of false negatives that could exclude some of their most promising drugs.

With the Dose-Response software controls and standards can be scattered across an assay plate rather than restricted to particular columns or rows.

The Cherry-Picking software makes users of the Echo 550 or Echo 555 to choose specific compounds from library source plates and to transfer them to assay plates in a variety of ways including interplate and intraplate replicates, variable volume transfers and pooled transfers.

Fereshteh Lesani, Labcyte marketing specialist said, "These new software packages were developed in close coordination with current users of Echo technology."

"With the software, researchers can choose to duplicate existing protocols or switch to new protocols that offer superior results via the elimination of serial or aqueous dilutions and through the improvement of assay plate layout."

"Based on the expressed needs of users, we expect that these two new software products will increase drug discovery throughput while improving the quality of the results."